Related Experiment Video
Updated: Feb 27, 2026
Comprehensive DNA Methylation Analysis Using a Methyl-CpG-binding Domain Capture-based Method in Chronic Lymphocytic Leukemia Patients
Published on: June 16, 2017
Comprehensive DNA Methylation Analysis Using a Methyl-CpG-binding Domain Capture-based Method in Chronic Lymphocytic
Santhilal Subhash1, Meena Kanduri2
1Department of Medical Genetics, Institute of Biomedicine, Gothenburg University.
Abstract:
The role of long noncoding RNAs (lncRNAs) in cancer is coming to the forefront due to growing interest in understanding their mechanistic functions during cancer development and progression. Despite this, the global epigenetic regulation of lncRNAs and repetitive sequences in cancer has not been well investigated, particularly in chronic lymphocytic leukemia (CLL). This study focuses on a unique approach: the immunoprecipitation-based capture of double-stranded, methylated DNA fragments using methyl-binding domain (MBD) proteins, followed by next-generation sequencing (MBD-seq). CLL patient samples belonging to two prognostic subgroups (5 IGVH mutated samples + 5 IGVH unmutated samples) were used in this study. Analysis revealed 5,800 hypermethylated and 12,570 hypomethylated CLL-specific differentially methylated genes (cllDMGs) compared to normal healthy controls. Importantly, these results identified several CLL-specific, differentially methylated lncRNAs, repetitive elements, and protein-coding genes with potential prognostic value. This work outlines a detailed protocol for an MBD-seq and bioinformatics pipeline developed for the comprehensive analysis of global methylation profiles in highly CpG-rich regions using CLL patient samples. Finally, a protein-coding gene and an lncRNA were validated using pyrosequencing, which is a highly quantitative method to analyze CpG methylation levels to further corroborate the findings from the MBD-seq protocol.
Insights
This study investigated long noncoding RNAs (lncRNAs) and DNA methylation in chronic lymphocytic leukemia (CLL). Methyl-binding domain sequencing (MBD-seq) identified numerous differentially methylated genes, lncRNAs, and repetitive elements with prognostic potential in CLL patients.
Area of Science:
- Epigenetics
- Genomics
- Cancer Biology
Background:
- Long noncoding RNAs (lncRNAs) are increasingly recognized for their roles in cancer development.
- Global epigenetic regulation of lncRNAs and repetitive sequences in cancer, especially chronic lymphocytic leukemia (CLL), remains understudied.
Purpose of the Study:
- To investigate the global epigenetic regulation of lncRNAs and repetitive sequences in chronic lymphocytic leukemia (CLL).
- To identify differentially methylated genes, lncRNAs, and repetitive elements with potential prognostic value in CLL.
Main Methods:
- Utilized methyl-binding domain protein (MBD) capture followed by next-generation sequencing (MBD-seq) to analyze DNA methylation profiles.
- Employed a bioinformatics pipeline for comprehensive analysis of CpG-rich regions in CLL patient samples.
- Validated findings using pyrosequencing for quantitative CpG methylation analysis.
Main Results:
- Identified 5,800 hypermethylated and 12,570 hypomethylated CLL-specific differentially methylated genes (cllDMGs) compared to healthy controls.
- Discovered several CLL-specific, differentially methylated lncRNAs, repetitive elements, and protein-coding genes.
- Established a detailed MBD-seq and bioinformatics protocol for global methylation profiling in CLL.
Conclusions:
- This study provides novel insights into the global methylation landscape of lncRNAs and repetitive elements in CLL.
- Identified potential prognostic biomarkers for CLL based on differential DNA methylation patterns.
- The developed MBD-seq protocol offers a robust method for analyzing methylation profiles in CpG-rich regions.
